Adagrasib Improves PFS Over Docetaxel in Patients with Previously Treated KRASG12C-mutated NSCLC By Ogkologos - August 20, 2025 607 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KRYSTAL-12 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR The ecDNA story – catching the mastermind behind cancer evolution February 20, 2023 How can we improve LGBTQ+ cancer care? – That Cancer Conversation... June 27, 2023 Second Drug Targeting KRAS G12C Shows Benefit in Mutated Non-Small-Cell Lung... March 25, 2021 Combining Niraparib with Abiraterone Acetate and Prednisone Significantly Improves rPFS in... October 22, 2025 Load more HOT NEWS From smart knives to virtual reality tumours: five innovations in understanding... Beloved Kansas City Jazz Singer Passes Away at 48 After 13-Year... Ensuring a Smooth Leadership Transition at NCI Impressive Responses to PD-1 Blockade in a Large Cohort of Children...
